Breast Surgery Practice Questions

Q: A 55-year-old female presents with a gradually enlarging, painless mass in her left breast. She also reports recent nipple retraction and peau d'orange skin changes. What is the most likely diagnosis?

Invasive ductal carcinoma. ***Invasive ductal carcinoma*** - The combination of a **gradually enlarging, painless mass**, **nipple retraction**, and **peau d'orange skin changes** are classic signs of advanced **invasive ductal carcinoma** [1]. - **Peau d'orange** occurs due to **lymphatic obstruction** by tumor cells, leading to edema and thickening of the skin, mimicking an orange peel. *Fibroadenoma* - This is a **benign tumor** typically found in younger women, presenting as a **mobile, rubbery, well-defined mass**. - It does not usually cause **nipple retraction** or **peau d'orange** changes. *Breast cyst* - **Breast cysts** are fluid-filled sacs that are often **tender** or **painful** and can fluctuate in size with the menstrual cycle. - They typically present as **smooth, mobile masses** and do not cause the advanced signs like **nipple retraction** or **peau d'orange**. *Ductal carcinoma in situ* - **Ductal carcinoma in situ (DCIS)** is a **non-invasive cancer** confined to the milk ducts [1]. - It often presents as **microcalcifications on mammography** and typically does not manifest with palpable masses, nipple retraction, or peau d'orange unless associated with an invasive component [1].

Q: A 45-year-old female presents with a lump in the breast and axillary lymphadenopathy. What is the most likely diagnosis?

Breast cancer. ***Breast cancer*** - The presence of a **breast lump** and **axillary lymphadenopathy** in a 45-year-old woman is highly suggestive of breast cancer. - **Axillary lymphadenopathy** in this context often indicates metastatic spread. *Fibroadenoma* - While fibroadenomas cause breast lumps, they are typically **benign** and do not present with associated **lymphadenopathy**. - They are more common in younger women and often feel rubbery and mobile. *Mastitis* - This is an **inflammatory condition** of the breast, usually associated with pain, redness, warmth, and fever. - Although it can cause a lump, it rarely presents with **axillary lymphadenopathy** without prominent inflammatory signs. *Breast cyst* - Breast cysts are **fluid-filled sacs** that can present as breast lumps, often feeling smooth and mobile. - They are benign and do not typically cause **axillary lymphadenopathy** unless severely inflamed or infected, which would present with other symptoms.

Q: What is the treatment of choice for duct ectasia of the breast?

Microdochectomy. ***Microdochectomy (Central Duct Excision)*** - For **symptomatic duct ectasia** that fails conservative management, the treatment involves **surgical excision of the affected duct(s)**, typically performed as **central duct excision** or **microdochectomy**. - This procedure removes the **dilated, inflamed subareolar ducts** while preserving healthy breast tissue. - **First-line treatment** is conservative (reassurance, antibiotics if infected, warm compresses), but surgery is indicated for **persistent nipple discharge, pain, or recurrent infections**. - Note: Some texts refer to major duct excision (Hadfield's operation) for extensive disease; microdochectomy is appropriate for localized symptomatic ducts. *Lobectomy* - Lobectomy refers to removal of a **lobe of an organ** (e.g., lung, liver, thyroid) and is **not applicable to breast surgery**. - This term is incorrectly used in breast pathology context. *Mastectomy* - Mastectomy involves **complete breast removal** and is vastly **excessive for benign duct ectasia**. - Reserved for **malignancy** or **high-risk prophylactic cases**, not benign ductal conditions. *Lumpectomy* - Lumpectomy is used for **discrete breast masses** (benign or malignant tumors) with surrounding margin excision. - Not the specific procedure for **ductal pathology** like duct ectasia, which requires targeted duct excision rather than mass removal.

Q: A 35-year-old female presents with a mass in her right breast. On examination, the mass is firm, mobile, and non-tender. What is the most likely diagnosis?

Fibroadenoma. ***Fibroadenoma*** - Fibroadenomas are common **benign breast tumors** in young women, presenting as **firm, mobile, non-tender masses**. - They are typically well-defined and can be described as **"rubbery"** or **"slippery"** on palpation due to their mobility. *Breast abscess* - A breast abscess typically presents with signs of **inflammation and infection**, including **pain, redness, warmth, and tenderness**. - The mass would usually be **fluctuant** and accompanied by systemic symptoms like fever, which are absent in this case. *Invasive ductal carcinoma* - Invasive ductal carcinoma often presents as a **hard, irregular, fixed mass** that may be **tender or non-tender**. - It is more common in **older women** and is less likely to be mobile compared to a fibroadenoma. *Ductal carcinoma in situ* - Ductal carcinoma in situ (DCIS) is a **non-invasive cancer** that often presents as **microcalcifications on mammography** and is typically not palpable as a distinct, mobile mass. - If palpable, it would likely be an **irregular or ill-defined area of thickening**, not a smoothly mobile mass.

Q: A 40-year-old woman with a family history of early-onset breast cancer undergoes genetic testing and is found to have a BRCA1 mutation. What is the most appropriate management option for her?

Prophylactic mastectomy. ***Prophylactic mastectomy*** - For a woman with a **BRCA1 mutation** and a family history of early-onset breast cancer, prophylactic mastectomy significantly **reduces the risk of developing breast cancer** by over 90%. - This aggressive preventive measure is considered appropriate due to the **high lifetime risk** of breast cancer associated with BRCA1 mutations [1]. *Annual mammography* - While important for surveillance, **mammography is a screening tool**, not a preventive measure, and may not be sufficient on its own for individuals with a high genetic risk like BRCA1 mutation carriers [1]. - BRCA1-associated cancers can be **aggressive and develop quickly**, making early detection challenging even with annual imaging, and mammography has limitations in dense breasts. *Tamoxifen therapy* - **Tamoxifen** is a **selective estrogen receptor modulator (SERM)** used for breast cancer prevention, but it's more effective for **estrogen receptor-positive (ER+) breast cancers**. - **BRCA1-associated breast cancers** are often **triple-negative (ER-/PR-/HER2-)** and therefore less likely to respond to tamoxifen's mechanism of action. *Ovarian cancer screening* - While BRCA1 mutations also increase the risk of ovarian cancer, and ovarian cancer screening is important, the question specifically asks for the most appropriate management *for her*, implying a focus on breast cancer given the context. - **Ovarian cancer screening**, typically involving transvaginal ultrasound and Ca-125, has **limited effectiveness** for early detection and is not a primary preventive measure for breast cancer.

Q: A 40-year-old woman presents with a mass in the right breast, and a biopsy confirms breast cancer. Which lymph nodes should be checked first for metastasis?

Axillary nodes. ***Axillary nodes*** - The **axillary lymph nodes** are the primary drainage site for the majority of the **breast lymphatic system**. - Therefore, these are the **first regional lymph nodes** to be checked for metastasis in breast cancer staging. *Inguinal nodes* - **Inguinal lymph nodes** drain the lower extremities, perineum, and external genitalia, not the breast. - Metastasis to these nodes from breast cancer would indicate widespread, **distant disease**, not initial regional spread. *Cervical nodes* - **Cervical lymph nodes** drain the head and neck region. - While possible in very advanced or specific cases, this would not be the **first site of metastasis** from primary breast cancer. *Mediastinal nodes* - **Mediastinal lymph nodes** are located in the chest cavity and primarily drain organs within the mediastinum. - Metastasis to these nodes from breast cancer would represent a **more advanced stage** of disease involving internal lymphatic spread, not the initial regional drainage.

Q: A 40-year-old female presents with a 2 cm breast mass detected on routine mammography. A biopsy confirms invasive ductal carcinoma. Which of the following is the most important clinical factor in determining the feasibility of breast-conserving surgery (BCS) versus mastectomy?

Tumor size relative to breast size. ***Tumor size relative to breast size*** - The **ratio of tumor size to breast size** is crucial for achieving clear surgical margins and a cosmetically acceptable outcome with **breast-conserving surgery (BCS)**. A small tumor in a large breast is more amenable to BCS. - If the tumor is large relative to the breast, adequate resection with clear margins might result in significant **breast disfigurement**, making a mastectomy a more viable option. *Patient’s genetic risk factors* - While **genetic risk factors** (e.g., BRCA mutations) are important for assessing future cancer risk and considering prophylactic mastectomy, they do not directly dictate the choice between BCS and mastectomy for an *existing* isolated tumor. - Genetic mutations primarily influence long-term risk management and contralateral breast cancer risk, not the immediate surgical approach for the current treatable lesion. *Patient preference* - **Patient preference** is undoubtedly important and should always be considered in shared decision-making. However, it is not the *most important* factor that determines the *feasibility and oncologic safety* of one surgery over another. - Clinical factors like tumor characteristics and anatomical considerations often dictate which surgical options are medically appropriate before patient preference finalizes the choice. *None of the options* - This option is incorrect because the **relative tumor size to breast size** is a highly significant factor in determining the appropriateness and success of breast-conserving surgery.

Q: A 25-year-old female presents with a palpable breast lump. An ultrasound shows a well-defined, hypoechoic lesion. What is the most likely diagnosis?

Fibroadenoma. ***Fibroadenoma*** - A **fibroadenoma** is the **most common benign breast tumor** in young women, typically presenting as a **palpable, mobile, well-defined lump**. - **Ultrasound imaging characteristically shows a well-defined, oval, hypoechoic solid lesion** with smooth margins. - This is the **classic presentation** matching the clinical scenario of a 25-year-old with a well-defined hypoechoic lesion. *Breast carcinoma* - **Breast carcinoma** in young women can present with a **palpable lump**, but ultrasound typically reveals an **irregularly shaped, ill-defined, hypoechoic mass with spiculation, posterior acoustic shadowing, or microcalcifications**. - The **well-defined smooth margins** make carcinoma unlikely in this case. *Breast cyst* - A **breast cyst** appears on ultrasound as a **well-defined, anechoic (not hypoechoic) lesion with posterior acoustic enhancement**. - Cysts are **fluid-filled structures** that are anechoic (black), whereas this lesion is described as **hypoechoic (gray)**, indicating a **solid mass**. *Breast abscess* - A **breast abscess** typically presents with **inflammatory signs**: pain, warmth, erythema, and fever, which are **not mentioned** in this presentation. - Ultrasound shows a **complex fluid collection with internal debris and septations**, not a simple well-defined hypoechoic solid lesion.

Q: What is the most effective primary prevention measure for breast cancer in a high-risk patient with a family history of a BRCA1 mutation?

Preventive mastectomy. ***Preventive mastectomy*** - A **bilateral prophylactic mastectomy** significantly reduces the risk of breast cancer (by over 90%) in high-risk individuals, especially those with **BRCA1/2 mutations**. This is considered the most effective primary prevention strategy due to direct removal of at-risk tissue. - This intervention is chosen when the patient has a very high lifetime risk of developing breast cancer due to strong genetic predisposition, aiming to prevent the disease's occurrence rather than detecting it early. *Routine breast screening* - **Routine breast screening** (e.g., mammograms, MRI) is a secondary prevention measure, focusing on **early detection** of cancer, not its prevention. - While important for surveillance, it does not prevent cancer from developing in a high-risk individual with a **BRCA1 mutation**, where lifetime risk can be over 50%. *Tamoxifen therapy* - **Tamoxifen** is a selective estrogen receptor modulator (SERM) that can reduce breast cancer risk, but it's considered a **chemopreventive agent**, offering partial risk reduction rather than complete prevention. - Its effectiveness is generally lower than prophylactic mastectomy, and it carries potential side effects, making it a less definitive primary prevention strategy for the highest risk patients. *Regular exercise regimen* - **Regular exercise** contributes to overall health and can modestly **lower cancer risk** in the general population by maintaining a healthy weight and reducing systemic inflammation. - However, for an individual with a strong genetic predisposition like a **BRCA1 mutation**, lifestyle interventions alone are insufficient as a primary prevention measure to significantly mitigate their exceptionally high risk.

Question 1

A 55-year-old female presents with a gradually enlarging, painless mass in her left breast. She also reports recent nipple retraction and peau d'orange skin changes. What is the most likely diagnosis?

Accepted Answer

Invasive ductal carcinoma

Answer

Fibroadenoma

Answer

Breast cyst

Answer

Ductal carcinoma in situ

Question 2

What is the impact of sentinel lymph node biopsy (SLNB) compared to axillary lymph node dissection (ALND) on lymphedema rates in patients with breast carcinoma?

Accepted Answer

SLNB is associated with lower lymphedema rates compared to ALND.

Answer

SLNB is less effective in controlling cancer compared to ALND.

Answer

ALND is associated with lower lymphedema rates than SLNB.

Answer

SLNB and ALND have similar rates of lymphedema.

Question 3

A 45-year-old female presents with a lump in the breast and axillary lymphadenopathy. What is the most likely diagnosis?

Accepted Answer

Breast cancer

Answer

Fibroadenoma

Answer

Mastitis

Answer

Breast cyst

Question 4

What is the treatment of choice for duct ectasia of the breast?

Accepted Answer

Microdochectomy

Answer

Lobectomy

Answer

Mastectomy

Answer

Lumpectomy

Question 5

A 35-year-old female presents with a mass in her right breast. On examination, the mass is firm, mobile, and non-tender. What is the most likely diagnosis?

Accepted Answer

Fibroadenoma

Answer

Breast abscess

Answer

Invasive ductal carcinoma

Answer

Ductal carcinoma in situ

Question 6

A 40-year-old woman with a family history of early-onset breast cancer undergoes genetic testing and is found to have a BRCA1 mutation. What is the most appropriate management option for her?

Accepted Answer

Prophylactic mastectomy

Answer

Annual mammography

Answer

Tamoxifen therapy

Answer

Ovarian cancer screening

Question 7

A 40-year-old woman presents with a mass in the right breast, and a biopsy confirms breast cancer. Which lymph nodes should be checked first for metastasis?

Accepted Answer

Axillary nodes

Answer

Inguinal nodes

Answer

Cervical nodes

Answer

Mediastinal nodes

Question 8

A 40-year-old female presents with a 2 cm breast mass detected on routine mammography. A biopsy confirms invasive ductal carcinoma. Which of the following is the most important clinical factor in determining the feasibility of breast-conserving surgery (BCS) versus mastectomy?

Accepted Answer

Tumor size relative to breast size

Answer

Patient preference

Answer

Patient’s genetic risk factors

Answer

None of the options

Question 9

A 25-year-old female presents with a palpable breast lump. An ultrasound shows a well-defined, hypoechoic lesion. What is the most likely diagnosis?

Accepted Answer

Fibroadenoma

Answer

Breast carcinoma

Answer

Breast cyst

Answer

Breast abscess

Question 10

What is the most effective primary prevention measure for breast cancer in a high-risk patient with a family history of a BRCA1 mutation?

Accepted Answer

Preventive mastectomy

Answer

Routine breast screening

Answer

Tamoxifen therapy

Answer

Regular exercise regimen

Breast Surgery — MCQs

Breast Surgery — MCQs

On this page

Practice by Chapter

Want unlimited practice?